3187-27-7

Usage

Uses

Used in Chemical Synthesis:
Cyclohexane-1,1-diethanol is used as a precursor in the synthesis of other organic compounds, leveraging its diol functionality to form a variety of chemical products.
Used in Solvent Applications:
In the chemical industry, cyclohexane-1,1-diethanol is used as a solvent for various processes due to its ability to dissolve a wide range of substances.
Used in Polymer and Plastics Production:
The diol functionality in cyclohexane-1,1-diethanol makes it a useful ingredient in the production of polymers, resins, and plastics, contributing to the formation of these materials' structures.
Used in Personal Care Formulation:
Cyclohexane-1,1-diethanol is used as a surfactant and emulsifier in the formulation of personal care products such as shampoos and lotions, helping to stabilize mixtures and improve product performance.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, cyclohexane-1,1-diethanol could potentially be used in the pharmaceutical industry for the development of drug formulations or as an intermediate in the synthesis of pharmaceutical compounds, given its versatility in chemical synthesis.
Each application takes advantage of cyclohexane-1,1-diethanol's unique properties, such as its solubility, reactivity, and ability to act as a surfactant or emulsifier, making it a versatile chemical with a wide range of industrial and commercial uses.

InChI:InChI=1/C10H20O2/c11-8-6-10(7-9-12)4-2-1-3-5-10/h11-12H,1-9H2

Upstream product

• 4355-15-1 2,4-dioxo-3-azaspiro[5.5]undecane-1,5-dicarbonitrile 
• 70197-61-4 Dimethyl 1,1-cyclohexanediacetate 
• 108667-25-0 cyclohexylidenedi-acetic acid diethyl ester 
• 4355-11-7 1,1-cyclohexanediacetic acid 

Downstream Products

• 180-45-0 3-oxa-spiro[5.5]undecane 
• 3187-34-6 1,1-bis-(2-bromo-ethyl)-cyclohexane 
• 70197-51-2 [1-(2-oxo-ethyl)-cyclohexyl]-acetaldehyde 
• 518285-27-3 2-[1-(2-Benzyloxyethyl)cyclohexyl]ethanol 
• 4375-49-9 3-benzyl-3-azaspiro[5.5]undecane 
• 6051-08-7 3-oxaspiro[5.5]undecan-2-one 
• 518285-18-2 2-[1-[2-(tert-Butyldiphenylsiloxy)ethyl]cyclohexyl]ethanol 
• 102760-07-6 1,1-bis-[2-(4-nitro-phenoxy)-ethyl]-cyclohexane 
• 114722-07-5 1,1-bis-[2-(4-amino-phenoxy)-ethyl]-cyclohexane 
• 17065-15-5 1,1-Divinylcyclohexan 
• 891829-37-1 (E)-4-[1-((E)-3-Ethoxycarbonyl-allyl)-cyclohexyl]-but-2-enoic acid ethyl ester 
• 127747-07-3 1,1-di(2-methanesulfonyloxyethyl)cyclohexane 
• 57740-28-0 1,1-bis-[2-(toluene-4-sulfonyloxy)-ethyl]-cyclohexane 

Relevant academic research and scientific papers

A phosphine-free iron complex-catalyzed synthesis of cycloalkanes: Via the borrowing hydrogen strategy

Herein we report a diaminocyclopentadienone iron tricarbonyl complex catalyzed synthesis of substituted cyclopentane, cyclohexane and cycloheptane compounds using the borrowing hydrogen strategy in the presence of various substituted primary and secondary 1,n diols as alkylating reagents. Deuterium labeling experiments confirm that the diols were the hydride source in this cascade process. This journal is

Stereoselective synthesis of alicyclic ketones: A hydrogen borrowing approach

A highly diastereoselective annulation strategy for the synthesis of alicyclic ketones from diols and pentamethylacetophenone is described. This process is mediated by a commercially available iridium(III) catalyst, and provides efficient access to a wide range of cyclopentane and cyclohexane products with high levels of stereoselectivity. The origins of diastereoselectivity in the annulation reaction have been explored by a series of control experiments, which provides an explanation for how each stereocentre around the newly forged ring is controlled.

Stereoselective Synthesis of Cyclohexanes via an Iridium Catalyzed (5 + 1) Annulation Strategy

An iridium catalyzed method for the synthesis of functionalized cyclohexanes from methyl ketones and 1,5-diols is described. This process operates by two sequential hydrogen borrowing reactions, providing direct access to multisubstituted cyclic products with high levels of stereocontrol. This methodology represents a novel (5 + 1) strategy for the stereoselective construction of the cyclohexane core.

Macrocyclic cyclophanes with two and three α,ω-dichalcogena-1, 4-diethynylaryl units: Syntheses and structural properties

(Chemical Equation Presented) By means of four- and six-component cyclization reaction various cyclophanes were synthesized. The components were the di(lithium) salts of 1,4-di(ethynyl)benzene (11), 4,4′-di(ethynyl) biphenyl (13), 1,4-di(ethynyl)-2,5-di(n-hexyl)benzene (18), and 1,4-di(ethynyl)-2,5-di(n-propyl)benzene (19). These building blocks were reacted with α,ω-dithiocyanato-n-alkanes and α,ω- diselenocyanato-n-alkanes with n = 3-6. In the case of 10 also 1,1′-di(2-thiocyanatoethyl)cyclohexane (24) was reacted to afford a cyclophane comprising three subunits of 11. From most of the resulting macrocyclic cyclophanes (4(n) (n = 3, 5), 5, 6, 7(n), 8(n) (n = 3-6), 9(n) (n = 3, 5), and 10), we were able to grow single crystals. The X-ray analysis of 4(3), 7(3), 8(3), 8(4), 6, 7(5), and 8(5) revealed close contacts between the chalcogen atoms. These chalcogen-chalcogen interactions impose a ribbon-shape arrangement of molecules in 4(3) and a mutual crossing of two perdendicular planes built of 8(4) molecules. For 4(3) we found a close contact (3.28 A) between the π planes of two neighboring C6H4 rings of different molecules, whereas in 8(4) such a close contact (3.74 A) was due to an intermolecular interaction. Tubular stacking of the macrocyclic rings was found for 7(5) and 8(5) caused by a ladder-type intermolecular chalcogen-chalcogen interaction.

SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF

The present invention relates to a CXCR3 antagonist comprising a compound represented by formula (I) (wherein all the symbols have the same meaning as defined in the description), a salt thereof, a quaternary ammonium salt thereof, an N-oxide form thereof or a solvate thereof, or a prodrug thereof. This antagonist is useful as a preventive, therapeutic and/or progression-suppressing agent for a CXCR3-mediated disease such as an immune or an allergic disease [e.g., an atopic disease, an autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, glomerulonephritis, Sjogren's syndrome and the like), systemic inflammatory response syndrome (SIRS), a rejection response to transplanted organ, tissue and/or cell or the like], a gastrointestinal disease [e.g., an inflammatory bowel disease or the like], or a respiratory disease [e.g., asthma, a chronic obstructive pulmonary disease or the like].

Facile synthesis of α,α′ disubstituted N-hydroxypyrrolidines and N-hydroxypiperidines via double 1,4-addition of hydroxylamine

A versatile synthesis of α and α′ disubstituted N-hydroxypiperidine and N-hydroxypyrrolidine by consecutive double 1,4-addition of hydroxylamine on the corresponding bis α,β-unsaturated diester is described. This reaction takes place an environmentally friendly (ethanol/water) system and at room temperature.

4-(2-FUROYL)AMINOPIPERIDINE COMPOUND USEFUL AS THERAPEUTIC AGENT FOR ITCHING

There are provided compounds represented by the following general formula (I): [where R1 is 5-methylpyridin-2-yl, p-tolyl or mesityl, R 2 is one of the following general formulas (II)-(IX): (where R3 is C1-C4 alkyl, R4 is H or C1-C4 alkyl, R5 is H, 3-pyridylmethyl or 4-pyridylmethyl, and R6 is 2,4-dihydroxybenzyl, 3-pyridylmethyl or 4-pyridylmethyl), or when R1 is mesityl, R2 is the following formula (X)], and pharmaceutically acceptable salts thereof. The compounds exhibit pruritus-inhibiting action, and are useful for prevention or treatment of itching and pruritus caused by reaction against insect-inflicted wounds, reaction against environmental allergens, skin infections or external parasite infections, or caused to renal dialysis patient.

Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy) alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives

A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.

NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME,PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME

There are provided novel 4-(2-furoyl)aminopiperidines represented by the general formula (I), their synthetic intermediates, processes for their preparation and medicaments containing them. In the above formula, X is CH or N, and Y is a group of the following general formula (II), formula (II-a) or formula (III): wherein a, b and c are each an integer of 0-6; Z is CH2 or NH; W is O or S; T is O or N-R15 wherein R15 is H, a C1-C6 alkyl group, a benzyl group or a phenethyl group; and R1 is H, a C1-C6 alkoxycarbonyl group, a benzyloxycarbonyl group, or the like.The 4-(2-furoyl) aminopiperidine derivatives according to this invention possess opioid μ antagonistic activity and are useful for the treatment or prevention of side effects which are caused by μ receptors agonist and which are selected from constipation, nausea/emesis or itch, or for the treatment or prevention of idiopathic constipation, postoperative ileus, paralytic ileus, irritable bowel syndrome or chronic pruritus.

Alkylsubstituted Cyclopentanones via Hydrocarbonylating Cyclization of 1,4-Pentadiene Systems Mediated by Metal Carbonyls

3,3-Dialkyl-1,4-pentadienes 8 under the influence of metal carbonyls can be converted to unsymmetrically substituted cyclopentanones 9 by hydrocarbonylating cyclization with carbon monoxide and hydrogen or water.Starting from 1,1-divinylcycloalkanes of type 8 this method can also be used for the synthesis of spirocyclopentanones.The yields of cyclic ketones with the here used dienes are markedly better than with the unsubstituted 1,4-pentadiene itself.